Study On The Synthesis Of MGLN-A New Oral Hypoglycemic Drug For Type Ⅱ Diabetes

Mitiglinide (MGLN) is a new class of oral hypoglycemic drug for type II diabetes which can spur insulin secreting rapidly and reduce the high lever of postprandial blood sugar sharply and not cause the hypoglycemia or prostration of the pancreatic islets 3 -cell. So it has become the preferred drug for early and low-grade diabetics, which has not been produced in China and has good value.Studying on the synthesis of MGLN is going to introduce it into China and provide a base for further study on its Me-too drugs. In order to avoid the patent protection, we first designed and chose a non-patent route which began from the material diethyl succinate, and obtained the target compound which chemical structure was confirmed by 'H-NMR and 13C-NMR. Furthermore, we also researched two another routes, one was got through and the other is continued.Cis-hexahydroisoidolin is the pivotal intermediate of the MGLN. We chose two non-patent routes to synthesize it and took some improvements and innovations on its technics. The target intermediate was obtained and confirmed by 'H-NMR.